Blueprint Medicines (NASDAQ:BPMC) Cut to “Sell” at StockNews.com
StockNews.com lowered shares of Blueprint Medicines (NASDAQ:BPMC – Free Report) from a hold rating to a sell rating in a report published on Monday. Other equities analysts also recently issued reports about the stock. Wedbush reiterated an “outperform” rating and set a $128.00 price target on shares of Blueprint Medicines in a report on Friday. […]
StockNews.com lowered shares of Blueprint Medicines (NASDAQ:BPMC – Free Report) from a hold rating to a sell rating in a report published on Monday. Other equities analysts also recently issued reports about the stock. Wedbush reiterated an “outperform” rating and set a $128.00 price target on shares of Blueprint Medicines in a report on Friday. […]
